SK29999A3 - Antifungal combination therapy - Google Patents

Antifungal combination therapy Download PDF

Info

Publication number: SK29999A3
Authority: SK; Slovakia
Prior art keywords: spp; cryptococcus; candida; aspergillus; inhibitor
Prior art date: 1996-09-12

Application number

SK299-99A

Other languages

English (en)

Slovak (sk)

Inventor

Kenneth F Bartizal

George K Abruzzo

Amy M Flattery

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-12

Filing date

1997-09-09

Publication date

2000-02-14

1996-10-04 Priority claimed from GBGB9620739.4A external-priority patent/GB9620739D0/en

1997-09-09 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2000-02-14 Publication of SK29999A3 publication Critical patent/SK29999A3/sk

Links

238000002648 combination therapy Methods 0.000 title abstract description 6
229940121375 antifungal agent Drugs 0.000 title abstract 6
230000000843 anti-fungal effect Effects 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 claims abstract description 15
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims abstract description 14
OXVVQYCKEAJWFA-QVCGFCSKSA-N 10,12-dimethyl-tetradecanoic acid [3-(3-amino-1-hydroxy-propyl)-6-[1,2-dihydroxy-2-(4-hydroxy-phenyl)-ethyl]-11,20,21,25-tetrahydroxy-15-(1-hydroxy-ethyl)-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaaza-tricyclo[22.3.0.09,13]heptacos-18-yl]-amide Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OXVVQYCKEAJWFA-QVCGFCSKSA-N 0.000 claims abstract description 13
150000004291 polyenes Chemical class 0.000 claims abstract description 12
229960003942 amphotericin b Drugs 0.000 claims abstract description 11
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 8
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims abstract description 8
229960004884 fluconazole Drugs 0.000 claims abstract description 8
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims abstract description 8
229920000057 Mannan Polymers 0.000 claims abstract description 5
239000002213 purine nucleotide Substances 0.000 claims abstract description 5
239000002719 pyrimidine nucleotide Substances 0.000 claims abstract description 5
150000003230 pyrimidines Chemical class 0.000 claims abstract description 5
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims abstract description 4
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims abstract description 4
229940123047 Elongation factor inhibitor Drugs 0.000 claims abstract description 4
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims abstract description 4
229930182764 Polyoxin Natural products 0.000 claims abstract description 4
230000000844 anti-bacterial effect Effects 0.000 claims abstract description 4
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims abstract description 4
229960004413 flucytosine Drugs 0.000 claims abstract description 4
230000001939 inductive effect Effects 0.000 claims abstract description 4
229960004130 itraconazole Drugs 0.000 claims abstract description 4
229960004125 ketoconazole Drugs 0.000 claims abstract description 4
150000002632 lipids Chemical group 0.000 claims abstract description 4
229960002509 miconazole Drugs 0.000 claims abstract description 4
229960000988 nystatin Drugs 0.000 claims abstract description 4
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims abstract description 4
230000035699 permeability Effects 0.000 claims abstract description 4
229960001589 posaconazole Drugs 0.000 claims abstract description 4
RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims abstract description 4
OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 claims abstract description 4
OGGVRVMISBQNMQ-MDGIRFSOSA-N sordarin Chemical compound O[C@H]1[C@H](O)[C@H](OC)[C@@H](C)O[C@H]1OC[C@]1([C@@]2(C(C(C)C)=C3)C(O)=O)[C@H]3C[C@]2(C=O)[C@@H]2CC[C@@H](C)[C@H]2C1 OGGVRVMISBQNMQ-MDGIRFSOSA-N 0.000 claims abstract description 4
OGGVRVMISBQNMQ-UHFFFAOYSA-N sordarin Natural products OC1C(O)C(OC)C(C)OC1OCC1(C2(C(C(C)C)=C3)C(O)=O)C3CC2(C=O)C2CCC(C)C2C1 OGGVRVMISBQNMQ-UHFFFAOYSA-N 0.000 claims abstract description 4
BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims abstract description 4
229960004740 voriconazole Drugs 0.000 claims abstract description 4
241001527609 Cryptococcus Species 0.000 claims description 11
241000228212 Aspergillus Species 0.000 claims description 10
241000222120 Candida <Saccharomycetales> Species 0.000 claims description 10
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 10
244000053095 fungal pathogen Species 0.000 claims description 9
241000223682 Exophiala Species 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
241001480043 Arthrodermataceae Species 0.000 claims description 6
241000335423 Blastomyces Species 0.000 claims description 6
241000223203 Coccidioides Species 0.000 claims description 6
241000228402 Histoplasma Species 0.000 claims description 6
241001537205 Paracoccidioides Species 0.000 claims description 6
241000228143 Penicillium Species 0.000 claims description 6
241000223596 Pseudallescheria Species 0.000 claims description 6
241000235527 Rhizopus Species 0.000 claims description 6
230000037304 dermatophytes Effects 0.000 claims description 6
UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims description 5
241000223208 Curvularia Species 0.000 claims description 5
241000223218 Fusarium Species 0.000 claims description 5
241001149962 Sporothrix Species 0.000 claims description 5
241000223230 Trichosporon Species 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
241000223600 Alternaria Species 0.000 claims description 4
241000233866 Fungi Species 0.000 claims description 4
241000235070 Saccharomyces Species 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
241000233872 Pneumocystis carinii Species 0.000 claims description 3
239000003899 bactericide agent Substances 0.000 claims 1
229940126534 drug product Drugs 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
YEBIHIICWDDQOL-YBHNRIQQSA-N polyoxin Polymers O[C@@H]1[C@H](O)[C@@H](C(C=O)N)O[C@H]1N1C(=O)NC(=O)C(C(O)=O)=C1 YEBIHIICWDDQOL-YBHNRIQQSA-N 0.000 claims 1
150000003212 purines Chemical class 0.000 claims 1
150000003851 azoles Chemical class 0.000 abstract description 7
-1 nikkomycins Natural products 0.000 abstract description 4
PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 abstract description 3
229920002101 Chitin Polymers 0.000 abstract description 3
229940098178 ambisome Drugs 0.000 abstract description 3
150000001720 carbohydrates Chemical class 0.000 abstract description 3
239000003429 antifungal agent Substances 0.000 abstract 3
WWJFFVUVFNBJTN-UIBIZFFUSA-N (2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid Chemical class C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O)C(O)=O)[C@H](O)c1ccc(O)cn1 WWJFFVUVFNBJTN-UIBIZFFUSA-N 0.000 abstract 1
229930184499 Nikkomycin Natural products 0.000 abstract 1
WWJFFVUVFNBJTN-UHFFFAOYSA-N neopolyoxin C Natural products C=1C=C(O)C=NC=1C(O)C(C)C(N)C(=O)NC(C(O)=O)C(C(C1O)O)OC1N1C=CC(=O)NC1=O WWJFFVUVFNBJTN-UHFFFAOYSA-N 0.000 abstract 1
WWJFFVUVFNBJTN-VHDFTHOZSA-N nikkomycin Z Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)[C@H](NC(=O)[C@@H](N)[C@H](C)[C@H](O)C=2N=CC(O)=CC=2)C(O)=O)C=CC(=O)NC1=O WWJFFVUVFNBJTN-VHDFTHOZSA-N 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 26
230000000855 fungicidal effect Effects 0.000 description 8
241000221204 Cryptococcus neoformans Species 0.000 description 7
108010049047 Echinocandins Proteins 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000000417 fungicide Substances 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
241001225321 Aspergillus fumigatus Species 0.000 description 4
241000222122 Candida albicans Species 0.000 description 4
201000007336 Cryptococcosis Diseases 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
206010017533 Fungal infection Diseases 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
239000000890 drug combination Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
201000002909 Aspergillosis Diseases 0.000 description 1
208000036641 Aspergillus infections Diseases 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
229920001503 Glucan Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000001408 fungistatic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK299-99A 1996-09-12 1997-09-09 Antifungal combination therapy SK29999A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2632796P	1996-09-12	1996-09-12
GBGB9620739.4A GB9620739D0 (en)	1996-10-04	1996-10-04	Antifungal combination therapy
PCT/US1997/015987 WO1998010782A1 (fr)	1996-09-12	1997-09-09	Therapie antifongique combinee

Publications (1)

Publication Number	Publication Date
SK29999A3 true SK29999A3 (en)	2000-02-14

Family

ID=26310166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK299-99A SK29999A3 (en)	1996-09-12	1997-09-09	Antifungal combination therapy

Country Status (21)

Country	Link
EP (1)	EP0925070B1 (fr)
JP (1)	JP3288051B2 (fr)
KR (1)	KR100380871B1 (fr)
CN (1)	CN1235554A (fr)
AT (1)	ATE248625T1 (fr)
AU (1)	AU721334B2 (fr)
CA (1)	CA2265824C (fr)
CY (1)	CY2481B1 (fr)
CZ (1)	CZ88499A3 (fr)
DE (1)	DE69724626T2 (fr)
DK (1)	DK0925070T3 (fr)
EA (1)	EA002469B1 (fr)
EE (1)	EE03748B1 (fr)
ES (1)	ES2203819T3 (fr)
IL (1)	IL128870A0 (fr)
NO (1)	NO991207L (fr)
NZ (1)	NZ334446A (fr)
PL (1)	PL333282A1 (fr)
PT (1)	PT925070E (fr)
SK (1)	SK29999A3 (fr)
WO (1)	WO1998010782A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1056849C (zh) *	1994-11-08	2000-09-27	葛兰素惠尔康有限公司	抗真菌的粪壳菌素衍生物及其制备方法和其在制药中的应用
US6069126A (en) *	1996-09-12	2000-05-30	Merck & Co., Inc.	Antifungal combination therapy
AUPQ066399A0 (en)	1999-05-31	1999-06-24	Fujisawa Pharmaceutical Co., Ltd.	Antifungal combination use
AUPQ462399A0 (en) *	1999-12-13	2000-01-13	Fujisawa Pharmaceutical Co., Ltd.	New use
KR100680464B1 (ko) *	2000-06-28	2007-02-08	주식회사 하이닉스반도체	반도체 소자의 캐패시터 제조 방법
WO2002098463A1 (fr) *	2001-06-05	2002-12-12	The New Industry Research Organization	Compositions antifongiques
NZ561675A (en) *	2005-04-07	2010-07-30	Toyama Chemical Co Ltd	Pharmaceutical composition and method using antifungal agent in combination
TWI385169B (zh)	2005-10-31	2013-02-11	Eisai R&D Man Co Ltd	經雜環取代之吡啶衍生物及含有彼之抗真菌劑
PT2070536E (pt) *	2006-10-06	2012-03-06	Toyama Chemical Co Ltd	Composição farmacêutica que contém um derivado de fenilamidina e processo para utilização dessa composição farmacêutica em associação com um agente antifúngico
TWI426918B (zh) *	2007-02-12	2014-02-21	Merck Sharp & Dohme	Ｉｌ-２３拮抗劑於治療感染之用途
WO2009129525A2 (fr) *	2008-04-18	2009-10-22	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Cellobio-oligosaccharides antifongiques et anti-carie produits par la dextransucrase
CN102274215B (zh) *	2010-06-10	2013-04-10	吉林大学	一种具有与氟康唑协同抗真菌作用的增效剂
CN102274217B (zh) *	2010-06-10	2013-04-10	吉林大学	三氯生作为抗真菌药物氟康唑增效剂的新用途
CN102274216B (zh) *	2010-06-10	2013-04-10	吉林大学	一种提高氟康唑抗真菌作用的增效剂
WO2012060448A1 (fr)	2010-11-05	2012-05-10	エーザイ・アール・アンド・ディー・マネジメント株式会社	Composition pharmaceutique combinée en tant qu'agent antifongique
WO2012162412A2 (fr) *	2011-05-24	2012-11-29	Agraquest, Inc., A Delaware Corporation	Combinaisons synergiques de fongicides de type polyène et de peptides non ribosomaux et procédés d'utilisation associés
CN102319326A (zh) *	2011-07-23	2012-01-18	李玮	一种治疗脚癣的浸药卫生纸
CN114052029A (zh) *	2021-11-25	2022-02-18	兰州大学	具哌嗪和哌啶骨架的医用化合物在防治植物真菌病害中的用途
CN114652836B (zh) *	2022-03-25	2023-06-20	山东大学	T3ss小分子抑制剂及其筛选方法和应用
CN116473985B (zh) *	2023-03-29	2024-12-10	暨南大学	一种多烯类抗真菌药物组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5378804A (en) *	1993-03-16	1995-01-03	Merck & Co., Inc.	Aza cyclohexapeptide compounds

1997
- 1997-09-09 EP EP97941495A patent/EP0925070B1/fr not_active Expired - Lifetime
- 1997-09-09 IL IL12887097A patent/IL128870A0/xx unknown
- 1997-09-09 PL PL97333282A patent/PL333282A1/xx unknown
- 1997-09-09 DE DE69724626T patent/DE69724626T2/de not_active Expired - Lifetime
- 1997-09-09 AU AU43392/97A patent/AU721334B2/en not_active Ceased
- 1997-09-09 EA EA199900283A patent/EA002469B1/ru not_active IP Right Cessation
- 1997-09-09 DK DK97941495T patent/DK0925070T3/da active
- 1997-09-09 CN CN97199420A patent/CN1235554A/zh active Pending
- 1997-09-09 SK SK299-99A patent/SK29999A3/sk unknown
- 1997-09-09 ES ES97941495T patent/ES2203819T3/es not_active Expired - Lifetime
- 1997-09-09 CZ CZ99884A patent/CZ88499A3/cs unknown
- 1997-09-09 JP JP51380898A patent/JP3288051B2/ja not_active Expired - Fee Related
- 1997-09-09 WO PCT/US1997/015987 patent/WO1998010782A1/fr not_active Ceased
- 1997-09-09 AT AT97941495T patent/ATE248625T1/de active
- 1997-09-09 KR KR10-1999-7002052A patent/KR100380871B1/ko not_active Expired - Fee Related
- 1997-09-09 PT PT97941495T patent/PT925070E/pt unknown
- 1997-09-09 EE EEP199900088A patent/EE03748B1/xx not_active IP Right Cessation
- 1997-09-09 CA CA002265824A patent/CA2265824C/fr not_active Expired - Fee Related
- 1997-09-09 NZ NZ334446A patent/NZ334446A/xx unknown
1999
- 1999-03-11 NO NO991207A patent/NO991207L/no not_active Application Discontinuation
2004
- 2004-10-27 CY CY0400076A patent/CY2481B1/xx unknown

Also Published As

Publication number	Publication date
CY2481B1 (en)	2005-06-03
DE69724626T2 (de)	2004-07-29
PL333282A1 (en)	1999-11-22
NO991207D0 (no)	1999-03-11
JP3288051B2 (ja)	2002-06-04
EE9900088A (et)	1999-10-15
EA199900283A1 (ru)	1999-08-26
ES2203819T3 (es)	2004-04-16
ATE248625T1 (de)	2003-09-15
CA2265824A1 (fr)	1998-03-19
DK0925070T3 (da)	2003-12-01
EP0925070A1 (fr)	1999-06-30
NO991207L (no)	1999-05-11
JP2000503675A (ja)	2000-03-28
CZ88499A3 (cs)	1999-10-13
WO1998010782A1 (fr)	1998-03-19
KR20000036054A (ko)	2000-06-26
DE69724626D1 (de)	2003-10-09
NZ334446A (en)	2000-11-24
EP0925070B1 (fr)	2003-09-03
KR100380871B1 (ko)	2003-04-18
EE03748B1 (et)	2002-06-17
AU4339297A (en)	1998-04-02
IL128870A0 (en)	2000-06-01
EA002469B1 (ru)	2002-06-27
AU721334B2 (en)	2000-06-29
CN1235554A (zh)	1999-11-17
PT925070E (pt)	2003-12-31
CA2265824C (fr)	2004-11-09

Publication	Publication Date	Title
SK29999A3 (en)	2000-02-14	Antifungal combination therapy
Deresinski et al.	2003	Caspofungin
Jarvis et al.	2004	Micafungin
US6069126A (en)	2000-05-30	Antifungal combination therapy
Galgiani	1990	Fluconazole, a new antifungal agent
Ryder et al.	2001	Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species
Hoang	2001	Caspofungin acetate: an antifungal agent
Hoffman et al.	2000	Novel triazole antifungal agents
Nakajima et al.	1995	In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi
Graybill et al.	1997	Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
Joseph et al.	2007	Micafungin: a new echinocandin antifungal
Graybill et al.	1997	Treatment of murine disseminated candidiasis with L-743,872
US20100129434A1 (en)	2010-05-27	Compositions and methods for the treatment of mucormycosis and other fungal diseases
Harari	1999	Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients
Groll et al.	2006	Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections
US7375081B2 (en)	2008-05-20	Therapeutic combination of a pneumocandin derivative and an antifungal agent
Zaas et al.	2005	Micafungin: the US perspective
Saravolatz et al.	2003	Caspofungin
MXPA99002401A (en)	1999-09-01	Antifungal combination therapy
Walsh et al.	1992	Immunomodulation and antifungal therapy of experimental invasive candidosis, histoplasmosis and aspergillosis: recent advances and concepts
HUP0000127A2 (hu)	2000-06-28	Több hatóanyagot tartalmazó antimikotikus kompozíció
US20220257578A1 (en)	2022-08-18	Composition and method for treating candida auris infection
KR20250102476A (ko)	2025-07-07	산화 아연 및 아졸계 화합물의 병용 요법을 이용한 피부 감염증의 치료 방법
Thakare et al.	2020	Rezafungin acetate
Chopra et al.	2020	Rezafungin acetate. 1, 3-beta-Glucan synthase inhibitor, Antifungal agent